Oracea
ApprovedSmall molecule
Oracea is one of 63 small molecule programs targeting Rosacea. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Rosacea
#DrugCompanyPhaseTrials
1Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Doryx
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Elavil
AstraZenecaPhase 2
Tofranil
SanofiPhase 2
Daliresp
AstraZenecaPhase 2
Otezla
AmgenPhase 2
Aimovig
AmgenPhase 2
Xifaxan
SSalix
Phase 2
Oracea
OOregon Health and Science University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Geographic Atrophy1 trial
Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)
Completed·—·Phase 2/3·NCT01782989·286 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oracea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details